Cerecor Inc. (NASDAQ:CERC) major shareholder Armistice Capital Master Fund bought 51,369 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The shares were acquired at an average price of $0.75 per share, for a total transaction of $38,526.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Friday, September 8th, Armistice Capital Master Fund bought 4,299 shares of Cerecor stock. The shares were acquired at an average price of $0.74 per share, for a total transaction of $3,181.26.
  • On Friday, September 1st, Armistice Capital Master Fund bought 39,479 shares of Cerecor stock. The shares were acquired at an average price of $0.76 per share, for a total transaction of $30,004.04.
  • On Tuesday, August 29th, Armistice Capital Master Fund bought 113,649 shares of Cerecor stock. The shares were acquired at an average price of $0.73 per share, for a total transaction of $82,963.77.
  • On Thursday, August 24th, Armistice Capital Master Fund bought 120,435 shares of Cerecor stock. The shares were acquired at an average price of $0.66 per share, for a total transaction of $79,487.10.
  • On Monday, August 21st, Armistice Capital Master Fund bought 219,792 shares of Cerecor stock. The shares were acquired at an average price of $0.60 per share, for a total transaction of $131,875.20.
  • On Wednesday, August 16th, Armistice Capital Master Fund bought 954,228 shares of Cerecor stock. The shares were acquired at an average price of $0.61 per share, for a total transaction of $582,079.08.

Shares of Cerecor Inc. (CERC) traded up 1.9351% during mid-day trading on Friday, hitting $0.7849. 191,492 shares of the stock traded hands. The firm has a 50 day moving average of $0.69 and a 200 day moving average of $0.66. The company’s market cap is $20.45 million. Cerecor Inc. has a 12 month low of $0.34 and a 12 month high of $5.60.

Cerecor (NASDAQ:CERC) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.15. The firm had revenue of $0.16 million for the quarter. Cerecor had a negative net margin of 1,106.99% and a negative return on equity of 1,325.84%. Equities analysts anticipate that Cerecor Inc. will post ($1.07) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/23/cerecor-inc-cerc-major-shareholder-purchases-38526-75-in-stock.html.

Cerecor Company Profile

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.